Diffuse cutaneous systemic sclerosis
MONDO:0016356Diffuse cutaneous systemic sclerosis (dcSSc) is a subtype of Systemic Sclerosis (SSc) characterized by truncal and acral skin fibrosis with an early and significant incidence of diffuse involvement (interstitial lung disease, oliguric renal failure, diffuse gastrointestinal disease, and myocardial involvement).
Also known as: dSSc, diffuse cutaneous systemic scleroderma, progressive cutaneous systemic scleroderma, progressive cutaneous systemic sclerosis, DcSSc
66 clinical trials for this condition and its sub-types, 30 tagged with Diffuse cutaneous systemic sclerosis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
Can a new pill ease the hardening skin of systemic sclerosis?
Disease control Not yet recruitingThis phase II trial is testing an experimental tablet called TollB-001 in adults with systemic sclerosis, a rare autoimmune disease that causes skin thickening and can affect internal organs. The study aims to see whether the drug can improve skin symptoms and overall well-being …
Phase 2 • Sponsor: Toll Biotech Co. Ltd. (Beijing) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New antibody drug firsekibart tested for scleroderma skin thickening
Disease control Not yet recruitingThis early-stage trial will test a new drug called firsekibart in 30 people with systemic sclerosis (scleroderma), a disease that causes skin thickening and organ damage. Firsekibart is an antibody that blocks a protein involved in inflammation. The study will measure changes in …
Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Experimental cell infusion aims to tame childhood autoimmune diseases
Disease control Not yet recruitingThis early-stage trial will test a new cell therapy called YTS109 in 12 children aged 5 to 17 with severe autoimmune diseases like lupus or scleroderma that have not responded to standard treatments. The children will receive a single infusion of these cells, and researchers will…
Phase 1 • Sponsor: Children's Hospital of Fudan University • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Could blocking TL1A stop skin scarring in scleroderma? early lab study hints at possibility
Knowledge-focused Not yet recruitingThis study will test if blocking a protein called TL1A can reverse skin scarring in systemic sclerosis, a rare autoimmune disease. Researchers will take blood and skin samples from 10 patients with early diffuse scleroderma and 10 healthy people. They will treat the samples in th…
Sponsor: Fondazione Policlinico Universitario Campus Bio-Medico • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC